Published in Nature on April 03, 2008
Uncovering the 'ORIGINS' of Diabetes (ORIGINS) | NCT02226640
Systems medicine: the future of medical genomics and healthcare. Genome Med (2009) 3.85
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev (2013) 3.44
Estimating Individualized Treatment Rules Using Outcome Weighted Learning. J Am Stat Assoc (2012) 3.13
A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med (2010) 2.88
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
Identification of high-quality cancer prognostic markers and metastasis network modules. Nat Commun (2010) 2.54
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A (2009) 2.32
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31
Visualizing multidimensional cancer genomics data. Genome Med (2013) 2.19
RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem Cell Biol (2008) 2.13
Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A (2013) 2.12
3'-end sequencing for expression quantification (3SEQ) from archival tumor samples. PLoS One (2010) 1.91
Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med (2010) 1.84
Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) (2009) 1.71
Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS One (2010) 1.65
Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res (2011) 1.59
Gene expression and network-based analysis reveals a novel role for hsa-miR-9 and drug control over the p38 network in glioblastoma multiforme progression. Genome Med (2011) 1.54
Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer (2010) 1.54
Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer (2011) 1.47
HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget (2013) 1.29
PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem (2011) 1.28
Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol (2014) 1.28
A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker. Mol Cell Proteomics (2011) 1.27
Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer (2009) 1.23
Estrogen biology: new insights into GPER function and clinical opportunities. Mol Cell Endocrinol (2014) 1.23
The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol (2012) 1.21
Optimally discriminative subnetwork markers predict response to chemotherapy. Bioinformatics (2011) 1.17
Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis. Ann Rheum Dis (2009) 1.16
Review of extracting information from the Social Web for health personalization. J Med Internet Res (2011) 1.14
Proteotoxic stress of cancer: implication of the heat-shock response in oncogenesis. J Cell Physiol (2012) 1.09
Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun (2015) 1.08
Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov (2011) 1.07
Multiplexed DNA repair assays for multiple lesions and multiple doses via transcription inhibition and transcriptional mutagenesis. Proc Natl Acad Sci U S A (2014) 1.06
A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood (2008) 1.06
Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Res (2010) 1.05
Co-clustering phenome-genome for phenotype classification and disease gene discovery. Nucleic Acids Res (2012) 1.05
Toward better benchmarking: challenge-based methods assessment in cancer genomics. Genome Biol (2014) 1.05
Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog (2011) 1.05
Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis. Breast Cancer Res (2013) 1.03
Similarity-based methods for potential human microRNA-disease association prediction. BMC Med Genomics (2013) 1.02
Improved RNA preservation for immunolabeling and laser microdissection. RNA (2009) 1.02
Constrained mixture estimation for analysis and robust classification of clinical time series. Bioinformatics (2009) 1.00
Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo. Proc Natl Acad Sci U S A (2013) 1.00
The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies. Langenbecks Arch Surg (2012) 0.99
Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer. BMC Cancer (2013) 0.99
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges. Cell (2015) 0.99
Emerging technologies for the clinical microbiology laboratory. Clin Microbiol Rev (2014) 0.98
Do two machine-learning based prognostic signatures for breast cancer capture the same biological processes? PLoS One (2011) 0.98
BioXpress: an integrated RNA-seq-derived gene expression database for pan-cancer analysis. Database (Oxford) (2015) 0.97
Whole-Transcriptome profiling of formalin-fixed, paraffin-embedded renal cell carcinoma by RNA-seq. BMC Genomics (2014) 0.97
Future research perspectives on environment and health: the requirement for a more expansive concept of translational cancer research. Environ Health (2011) 0.97
Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform. PLoS One (2010) 0.97
Estimation of treatment policies based on functional predictors. Stat Sin (2014) 0.96
Empirical chemosensitivity testing in a spheroid model of ovarian cancer using a microfluidics-based multiplex platform. Biomicrofluidics (2013) 0.95
TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Res (2014) 0.94
Ubiquitination-dependent regulation of signaling receptors in cancer. Genes Cancer (2010) 0.94
Modularity-based credible prediction of disease genes and detection of disease subtypes on the phenotype-gene heterogeneous network. BMC Syst Biol (2011) 0.94
How should we define STAT3 as an oncogene and as a potential target for therapy? JAKSTAT (2013) 0.93
Research status and funding trends of lung cancer biomarkers. J Thorac Dis (2013) 0.93
In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection. Cancer Res (2011) 0.93
Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol (2008) 0.92
Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens. BMC Cancer (2011) 0.92
Improved Statistical Methods are Needed to Advance Personalized Medicine. Open Transl Med J (2009) 0.91
A new view of carcinogenesis and an alternative approach to cancer therapy. Mol Med (2009) 0.90
Public health genomics: translating obesity genomics research into population health benefits. Obesity (Silver Spring) (2008) 0.90
Selecting cases for whom additional tests can improve prognostication. AMIA Annu Symp Proc (2012) 0.89
Genetics of breast cancer bone metastasis: a sequential multistep pattern. Clin Exp Metastasis (2014) 0.87
Whole blood gene expression profiling predicts therapeutic response at six months in patients with polyarticular juvenile idiopathic arthritis. Arthritis Rheumatol (2014) 0.87
Large-scale integrative network-based analysis identifies common pathways disrupted by copy number alterations across cancers. BMC Genomics (2013) 0.87
Stromal genes add prognostic information to proliferation and histoclinical markers: a basis for the next generation of breast cancer gene signatures. PLoS One (2012) 0.87
Prediction of the clinical outcome in invasive candidiasis patients based on molecular fingerprints of five anti-Candida antibodies in serum. Mol Cell Proteomics (2010) 0.86
The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypes. Anticancer Drugs (2014) 0.86
Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis. Br J Radiol (2012) 0.86
Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles. Nucleic Acids Res (2015) 0.85
Shared signatures between rheumatoid arthritis, systemic lupus erythematosus and Sjögren's syndrome uncovered through gene expression meta-analysis. Arthritis Res Ther (2014) 0.84
Genomic deregulation during metastasis of renal cell carcinoma implements a myofibroblast-like program of gene expression. Cancer Res (2010) 0.84
Network based consensus gene signatures for biomarker discovery in breast cancer. PLoS One (2011) 0.84
A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. Neoplasia (2010) 0.84
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer. Biomedicine (Taipei) (2014) 0.84
Development of a microarray platform for FFPET profiling: application to the classification of human tumors. J Transl Med (2009) 0.84
Expression of inflammation-mediated cluster of genes as a new marker of canine mammary malignancy. Vet Res Commun (2013) 0.84
In silico discovery of mitosis regulation networks associated with early distant metastases in estrogen receptor positive breast cancers. Cancer Inform (2013) 0.84
Network-constrained group lasso for high-dimensional multinomial classification with application to cancer subtype prediction. Cancer Inform (2015) 0.83
Evaluation of a high-throughput, microfluidics platform for performing TaqMan™ qPCR using formalin-fixed paraffin-embedded tumors. Bioanalysis (2013) 0.83
Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. Breast Cancer Res (2008) 0.83
Evidence for the importance of personalized molecular profiling in pancreatic cancer. Pancreas (2014) 0.83
Assessing the impact of mutations found in next generation sequencing data over human signaling pathways. Nucleic Acids Res (2015) 0.83
Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival. Oncotarget (2015) 0.83
Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies. BMC Syst Biol (2012) 0.82
Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. Genome Med (2012) 0.82
Assessment of kidney organ quality and prediction of outcome at time of transplantation. Semin Immunopathol (2011) 0.82
Rheonix CARD(®) Technology: An Innovative and Fully Automated Molecular Diagnostic Device. Point Care (2012) 0.82
Human breath analysis may support the existence of individual metabolic phenotypes. PLoS One (2013) 0.82
Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer. Oncotarget (2015) 0.82
Association of survivin splice variants with prognosis and treatment of breast cancer. World J Clin Oncol (2014) 0.81
Combining multiple hypothesis testing and affinity propagation clustering leads to accurate, robust and sample size independent classification on gene expression data. BMC Bioinformatics (2012) 0.81
Gene expression profiles in canine mammary carcinomas of various grades of malignancy. BMC Vet Res (2013) 0.81
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
A genomic and functional inventory of deubiquitinating enzymes. Cell (2005) 9.36
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 7.88
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature (2003) 6.53
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol (2006) 4.67
Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics (2006) 4.57
Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol (2006) 4.54
The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell (2005) 4.40
The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol (2005) 4.29
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01
Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta (2008) 3.74
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res (2008) 3.70
Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23
ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell (2009) 2.93
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol (2006) 2.91
The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell (2005) 2.73
Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem (2003) 2.14
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell (2010) 1.81
Expression profiling predicts outcome in breast cancer. Breast Cancer Res (2002) 1.81
The translation initiation factor 3f (eIF3f) exhibits a deubiquitinase activity regulating Notch activation. PLoS Biol (2010) 1.77
A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling. Genes Dev (2002) 1.65
E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell (2002) 1.59
Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood (2004) 1.56
Re-evaluating cell-cycle regulation by E2Fs. Cell (2006) 1.46
TBX-3, the gene mutated in Ulnar-Mammary Syndrome, is a negative regulator of p19ARF and inhibits senescence. J Biol Chem (2001) 1.46
E2F-7: a distinctive E2F family member with an unusual organization of DNA-binding domains. Oncogene (2004) 1.44
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol (2013) 1.38
Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells. Mol Cell (2005) 1.34
Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell (2009) 1.33
A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One (2009) 1.29
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov (2014) 1.27
A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat Cell Biol (2002) 1.25
New tools for functional mammalian cancer genetics. Nat Rev Cancer (2003) 1.22
PR72, a novel regulator of Wnt signaling required for Naked cuticle function. Genes Dev (2005) 1.21
Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle (2006) 1.17
TSPYL5 suppresses p53 levels and function by physical interaction with USP7. Nat Cell Biol (2010) 1.13
A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res (2006) 1.09
Transforming growth factor-beta requires its target plasminogen activator inhibitor-1 for cytostatic activity. J Biol Chem (2008) 1.09
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2007) 1.07
PR130 is a modulator of the Wnt-signaling cascade that counters repression of the antagonist Naked cuticle. Proc Natl Acad Sci U S A (2006) 1.07
Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nat Med (2011) 1.05
The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling. Mol Cancer Res (2010) 1.04
Cancer: cues for migration. Nature (2003) 0.97
A RNA interference screen identifies the protein phosphatase 2A subunit PR55gamma as a stress-sensitive inhibitor of c-SRC. PLoS Genet (2007) 0.95
UNC45A confers resistance to histone deacetylase inhibitors and retinoic acid. Mol Cancer Res (2009) 0.95
Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res (2010) 0.94
An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol (2013) 0.93
Understanding resistance to targeted cancer drugs through loss of function genetic screens. Drug Resist Updat (2012) 0.93
High incidence of thymic epithelial tumors in E2F2 transgenic mice. J Biol Chem (2003) 0.91
Constitutive E2F1 overexpression delays endochondral bone formation by inhibiting chondrocyte differentiation. Mol Cell Biol (2003) 0.91
TGF-β: an emerging player in drug resistance. Cell Cycle (2013) 0.90
A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. Mol Oncol (2013) 0.90
A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor-beta. J Biol Chem (2006) 0.89
Suppression of the p53-dependent replicative senescence response by lysophosphatidic acid signaling. Mol Cancer Res (2008) 0.87
Interleukin-1R-associated kinase 2 is a novel modulator of the transforming growth factor beta signaling cascade. Mol Cancer Res (2010) 0.87
Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs. Breast Cancer Res Treat (2011) 0.86
Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. Int J Biochem Cell Biol (2008) 0.86
Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E. Carcinogenesis (2009) 0.85
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. Int J Cancer (2014) 0.84
Resistance to targeted cancer drugs through hepatocyte growth factor signaling. Cell Cycle (2014) 0.84
Genetic and functional studies implicate synaptic overgrowth and ring gland cAMP/PKA signaling defects in the Drosophila melanogaster neurofibromatosis-1 growth deficiency. PLoS Genet (2013) 0.83
Functional annotation of deubiquitinating enzymes using RNA interference. Methods Enzymol (2005) 0.80
Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen. Clin Cancer Res (2009) 0.80
Wip-ing out cancer. Nat Genet (2004) 0.79
Cancer: Entangled pathways. Nature (2008) 0.79
An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression. Oncogene (2004) 0.77
Functional subtyping of breast cancer. Cancer Discov (2011) 0.75
Are short-term or long-term recurrence rates more important in breast cancer screening? Ann Intern Med (2008) 0.75